Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens

BACKGROUND: Cardiometabolic outcomes were investigated 3 years after switching to the 2-drug regimen dolutegravir/lamivudine (DTG/3TC) vs continuing 3-/4-drug tenofovir alafenamide (TAF)–based regimens in a multicenter phase 3 noninferiority study based on an open-label randomized design. METHOD: Ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Batterham, Rachel L, Espinosa, Nuria, Katlama, Christine, McKellar, Mehri, Scholten, Stefan, Smith, Don E, Ait-Khaled, Mounir, George, Nisha, Wright, Jonathan, Gordon, Lori A, Moodley, Riya, Wynne, Brian, van Wyk, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375426/
https://www.ncbi.nlm.nih.gov/pubmed/37520420
http://dx.doi.org/10.1093/ofid/ofad359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375426/
https://www.ncbi.nlm.nih.gov/pubmed/37520420
http://dx.doi.org/10.1093/ofid/ofad359

Ejemplares similares